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Background: High levels of opioid-related mortality, as well as morbidity, contribute to the excessive opioid-related
disease burden in North America, induced by high availability of opioids. While correlations between opioid
dispensing levels and mortality outcomes are well-established, fewer evidence exists on correlations with morbidity
(e.g., hospitalizations).
Methods: We examined possible overtime correlations between medical opioid dispensing and opioid-related
hospitalizations in Canada, by province, 2007–2016. For dispensing, we examined annual volumes of medical opioid
dispensing derived from a representative, stratified sample of retail pharmacies across Canada. Raw dispensing
information for ‘strong opioids’ was converted into Defined Daily Doses per 1000 population per day (DDD/1000/
day). Opioid-related hospitalization rates referred to opioid poisoning-related admissions by province, for fiscal years
2007–08 to 2016–17, drawn from the national Hospital Morbidity Database. We assessed possible correlations
between opioid dispensing and hospitalizations by province using the Pearson product moment correlation;
correlation values (r) and confidence intervals were reported.
Results: Significant correlations for overtime correlations between population-levels of opioid dispensing and
opioid-related hospitalizations were observed for three provinces: Quebec (r = 0.87, CI: 0.49–0.97; p = 0.002); New
Brunswick (r = 0.85;CI: 0.43–0.97; p = 0.004) and Nova Scotia (r = 0.78; CI:0.25–0.95; p = 0.012), with an additional
province, Saskatchewan, (r = 0.073; CI:-0.07–0.91;p = 0.073) featuring borderline significance.
Conclusions: The correlations observed further add to evidence on opioid dispensing levels as a systemic driver of
population-level harms. Notably, correlations were not identified principally in provinces with reported high
contribution levels (> 50%) of illicit opioids to mortality, which are not captured by dispensing data and so may
have distorted or concealed potential correlation effects due to contamination.
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North America – Canada and the US - has been home to
a severe public health crisis of opioid-related (i.e., morbid-
ity and mortality) harms since the early 2000s, initially
evolving in contexts of persistently high prescription opi-
oid (PO) availability [1–3]. This burden, specifically, has
involved excessively high levels of (e.g., overdose) mortal-
ity, even negatively affecting general population-based life
expectancy in both jurisdictions [4, 5]. Concretely, there
were 47,600 opioid-related deaths in the US, and 4100 in
Canada, respectively, in 2017, representing similar
population-based mortality rates [6, 7].
Most attention regarding acute opioid-related harms
has focused on mortality outcomes, as recently further
accelerated by widespread proliferation of highly toxic
illicit opioid products [6, 8, 9]. Less attention has been
given to morbidity outcomes, for example (non-fatal)
opioid-related poisonings or disorders. Recent US data
have demonstrated rising trends for opioid-related hos-
pitalizations post-2000 [10–12]. Opioid-related hospitali-
zations among public drug plan beneficiaries in Ontario
(Canada) increased by 55% from 2003 to 2013 [13].
North American studies have examined associations be-
tween population-levels of opioid-dispensing and adverse
outcomes towards improved understanding of the systemic
drivers of opioid-related harms. While substantive correla-
tions between opioid-dispensing and mortality have been
found for several populations and/or jurisdictions [14–16],
select investigations have established similar correlations
for morbidity outcomes. For example, strong associations
were found between US-based national prescription vol-
umes of major opioid formulations and related emergency
department (ED) visits over a 10-year period (1995–2004
[17];). Moderai et al. established similar correlations for
North Carolina (2008–2010); in Florida, associations be-
tween PO availability and morbidity were less pronounced
than for mortality (2009 [18, 19];). Strong correlations have
been ascertained between opioid-dispensing and opioid-
related substance treatment admissions in Ontario (2005–
2011 [14];). Furthermore, substantial congruence between
opioid dispensing and related hospitalizations have been
observed for Australian jurisdictions [20, 21].
In Canada, despite overall distinctly high levels of opi-
oid availability, opioid dispensing has considerably varied
inter-provincially, with up to 3-fold differences in stan-
dardized volumes. Over-time, an inversion trend has
been observed: While levels of opioid-dispensing consist-
ently increased until about 2012, some – but not all – prov-
inces have featured substantial declines thereafter [22].
In the context of the acute yet differentiated develop-
ments regarding opioid availability and related harms,
we examine possible over-time correlations between opi-
oid dispensing and opioid-related hospitalizations across
Canada for the period 2007–2016.Methods
We used national data on community-based PO dis-
pensing across Canada – i.e., here the 10 provinces – for
the study period; the vast majority (e.g., ~ 80%) of opioid
medications are dispensed through retail pharmacies
[22]. Raw prescription opioid dispensing data, including
both branded and generic medications, were obtained
from IQVIA’s Compuscript prescription database, drawn
from a representative, stratified, and continuously
refreshed sample of ~ 6000 retail pharmacies towards es-
timating pan-Canadian dispensing total through pat-
ented geo-spatial projection methodology as previously
used in related analyses [23–25]. Raw aggregate PO dis-
pensing data included the numbers of units dispensed by
product name, formulation and strength. These data
were converted to annual values of Defined Daily Doses
(DDD) per 1000 population per day (DDD/1000/day) as
the measuring unit, based on the WHO’s Anatomical
Chemical Classification as well as population statistics,
by province and year for the study period (2007–2016
[26, 27];. DDDs are the assumed average maintenance
dose per day for a drug used for its main indication for
an average adult. While limited in accuracy, DDDs are a
widely utilized measurement unit for comparative
population-level analyses, and superior to crude indica-
tors like prescription numbers [28]. We restricted our
data to ‘strong’ opioids, based on the WHO’s ‘pain
ladder’ i.e. excluding ‘weak’ opioids (e.g., codeine), as
well as methadone due to differential dispensing
modes as well as limited involvement in hospitaliza-
tions [22, 29].
Data on opioid-related hospitalizations in Canada
came from published data from the Canadian Institutes
of Health Information (CIHI)‘s Hospital Morbidity Data-
base (HMDB). The HMDB is a national data-holding on
administrative, clinical and demographic information on
inpatient separations from acute care hospitals (but ex-
cluding EDs) from provincial data-sources across
Canada [30, 31]. Opioid-related hospitalizations were
identified based on admissions and length-of-time in
hospital considered related to ‘significant opioid poison-
ings’, with discharge abstracts as the primary diagnosis,
or comprised selected secondary diagnostic types based
on ICD-10-CA codes (T40.0–4 and T40.6). Respective
data, reported in population-based rates (per 100,000)
were available by province for fiscal years (i.e., defined
formally in Canada from 01 April to 31 March of the
correspondingly following year) 2007/2008–2014/2015
and 2016/2017 (i.e., excluding data for 2015/16, as
these were not available from the original data-
source).
Possible correlations between annual provincial opioid
dispensing and opioid-related hospitalization rates were
assessed through the respective nine over-time data-pairs
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opioid-dispensing with corresponding hospitalization data
for the corresponding annual time units (e.g., 2016 and
2016/17). Using the Pearson product moment correlation,
ten province-specific correlation values and their 95% confi-
dence intervals (95%CI) were calculated using the cor.test
function of the R stats package (2018) [32].
Results
(see Table 1 for numeric data and Fig. 1 for correspond-
ing visualizations).
For strong opioid dispensing, in 2007 (first observation
year) the highest annual provincial rate was observed in
Ontario (11.6 DDD/1000/day) and the lowest rate was in
Quebec (4.9 DDD/1000/day) – constituting a > 2.3/1 ra-
tio. Correspondingly, in 2016 (last observation year)
Nova Scotia and New Brunswick featured the highest
(11.4 DDD/1000/day) and Quebec had the lowest (6.5
DDD/1000/day) strong opioid dispensing rate – consti-
tuting a 1.7/1 ratio. All provinces featured higher strong
opioid dispensing rates between the first and last obser-
vation year. While about half the provinces showed
inverting trends in strong opioid dispensing – with an-
nual levels initially rising and then decreasing – the
other half featured consistent increases in strong opioid
dispensing during the study period.
For opioid-related hospitalizations, in 2007/08 (first
observation year) the highest annual rate was observed
in Prince Edward Island (16.0/100,000) and the lowest
rate was observed in Newfoundland and Labrador (7.1/
100,000) – constituting a > 2.25/1 ratio. Correspondingly,
in 2016/17 (last observation year) British Columbia fea-
tured the highest (25.0/100,000) and Quebec had the
lowest (9.4/100,000) hospitalization rate – constituting
a > 2.6/1 ratio. All provinces reported higher opioid-
related hospitalization rates in 2016/17 compared toTable 1 Rates and correlations of opioid dispensing and opioid-rela
Legend: Acronyms of Provinces: BC British Columbia; AB Alberta; SK Saskatchewan;
Prince Edward Island; NL Newfoundland & Labrador
DDD Defined Daily Doses/1000population/day
Hosp Hospitalization
n.a.: data not available2007/08. The majority of provinces featured varying
(e.g., non-linear) trends in opioid-related hospitalization
rates during the observation period.
The strongest correlation between opioid dispensing
and hospitalization was observed for Quebec (r = 0.87,
95% Confidence Interval (95%CI): 0.49–0.97; p = 0.002);
the weakest for Prince Edward Island (r = 0.20; 95%CI:
− 0.53–0.76; n.s.). In a total of three provinces, signifi-
cant correlations were observed: Quebec (see above);
New Brunswick (r = 0.85; 95%CI: 0.43–0.97; p = 0.004)
and Nova Scotia (r = 0.78; 95%CI: 0.25–0.95; p = 0.012);
one province – Saskatchewan – (r = 0.073; 95%CI: −
0.07–0.91; p = 0.073) featured borderline significance
(see Table 1 for data).
Discussion
Opioid-related morbidity substantially contributes to the
extensive opioid-related disease and economic burden
observed across North America [33–35]. Strong in-
creases in opioid-related hospitalizations post-2000 have
been observed in the US, as well as other countries with
rising opioid availability [10, 12, 21, 36, 37].
We examined possible correlations between opioid
dispensing and opioid-related hospitalization rates across
Canada in contexts of most provinces featuring inversion
patterns for opioid dispensing during the study period
(2007–2016 [22];). These patterns reflect recent reduc-
tions in opioid availability following a variety of restrict-
ive measures (e.g., intensified prescription monitoring,
de-scheduling of select opioid formulations, restrictive
opioid prescription guidelines) in a wider context of con-
tinuously rising opioid-related mortality and morbidity
outcomes in Canada [3, 38, 39].
We identified significant correlations between opioid
dispensing and opioid-related hospitalization rates for
three (QC, NB, NS) of the ten provinces, with borderlineted hospitalizations, by province, in Canada 2007–2016
MN Manitoba; ON Ontario; QC Quebec; NB New Brunswick; NS Nova Scotia; PE
Fig. 1 Rates and correlations of opioid dispensing and opioid-related hospitalizations, by province, in Canada 2007–2016 (visual display)
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to an extensive body of evidence identifying correlations
between the volume of opioid availability and health harm
outcomes on population levels [14, 15, 19, 40]. While
these correlations were identified in select provinces, they
were not identified in most others. These selective find-
ings, however may not be coincidental when considering
key ecological dynamics. Importantly, opioid-related hos-
pitalizations data may comprise incidents related to both
licit and illicit opioids, as the data used do not discrimin-
ate between opioids by legal status [8, 10, 41]. However,
opioid availability data are limited to levels of medical opi-
oid dispensing only. These circumstances, consequently,
may involve a ‘contamination’ of hospitalization data
through illicit opioid-related cases and a subsequent dis-
tortion or concealment of possible correlation effects.
In Canada, population-levels of illicit opioid use have
been relatively limited, compared with high levels of
(medical and non-medical) PO use estimated at > 20%
and > 5%, respectively, in peak years around 2010 [42].
However, there have been strong increases in the avail-
ability of – highly potent and toxic – illicit synthetic opi-
oid products (e.g., fentanyl, carfentanyl products) in
Canada in more recent years, linked to substantial in-
creases in fatal poisonings due to acutely elevated risk
properties of these substances [4, 43, 44]. In this context,
we note that significant (including borderline) correla-
tions between opioid dispensing and hospitalizations
were found specifically in four of the five Canadian prov-
inces (PEI, NS, QC, NB, SK) reporting the lowest levels
of contributions (< 25%) of (mostly illicit) fentanyl or
fentanyl-analogue product involvement among opioid-
related mortality in 2017 (i.e., ‘low contamination’ prov-
inces); conversely, no correlations were observed in the
provinces (MN, ON, AB, BC) with fentanyl products
identified as a contributor to mortality in the majority
(> 50%) of fatalities in 2017 (i.e., ‘high contamination’
provinces [7, 8, 41];). Similarly differential – but consist-
ent with our results – patterns of illicit opioid involve-
ment in opioid-related hospitalizations have been shown
in analyses for select individual provinces [45]. These –
rather consistent – differentiation patterns in our eco-
logical study results allow to plausibly speculate that, in
the absence of illicit opioid-related ‘contamination’ ef-
fects, the strength of province-based correlation signals
between opioid dispensing and hospitalizations likely
would have been more pronounced.
In this context, our findings of select Canada-based
correlations between opioid dispensing and opioid-
related hospitalizations provide additional evidence on
associations between population-level opioid availability
and key adverse health outcomes [34, 46–48]. This asso-
ciation – at least while supply for non-medical opioid
use mostly involved prescription opioid products – hadsimple but essential implications: The higher the volume of
opioids dispensed into the population, the higher the levels
of consequential morbidity or mortality harms [15, 49, 50].
This insight provided a crucial knowledge base for guiding
opioid policy and medical practice control (e.g., prescription
guidance) in the distinct contexts of traditionally high opi-
oid availability in North America, combined with evidence
of only limited effectiveness of opioids for chronic pain
therapy [51–53]. Beyond these current contexts, where il-
licitly produced opioids have increasingly replaced
pharmaceutical opioids for non-medical use, these in-
sights may be helpful for settings where opioid avail-
ability is still low and preventive restraints can
facilitate appropriate balance between opioid availability
and related adverse health outcomes [5, 38, 54, 55]. As a
potentially relevant limitation for the present analyses, we
note that the (general population-level) data examined did
not include additional patient-level descriptors, or other
data variables that could have been used to examine pos-
sibly confounding factors in the correlations assessed.
Conclusions
Our study identified correlations between over-time
levels of prescription opioid dispensing and opioid-
related hospitalizations in several provinces across
Canada. These data further contribute to the evidence-
base of population levels of prescription opioid availabil-
ity and exposure, and opioid-related harms (e.g., morbid-
ity, mortality). Correlations were mostly not observed in
provincial jurisdictions where non-medical or illicitly
produced opioids (e.g., fentanyls) have played an increas-
ingly prevalent role in non-medical opioid use and
harms in recent years, likely as an adverse consequence
of recent restrictions on medical opioid availability
(which may mask further correlations in regards to the
specific data under study). Our study’s findings
emphasize the need to reasonably limit the overall avail-
ability of and exposure to opioids in the population for
general prevention.
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